东非未接受抗逆转录病毒治疗的成人中治疗前HIV-1耐药:系统综述与Meta分析
该系统综述与Meta分析纳入2017年1月1日至2022年4月30日发表的22项观察性研究、共5852例未接受抗逆转录病毒治疗的HIV感染者,评估东非新启动抗逆转录病毒治疗成人的治疗前HIV耐药(PDR)水平。合并PDR总患病率为10.0%(95%CI:7.9%-12.0%,I²=88.9%),NNRTI类为9.4%(95%CI:7.0%-11.9%,I²=90.4%),NRTI类为2.6%(95%CI:1.8%-3.4%,I²=69.2%),PI类为0.7%(95%CI:0.3%-1.2%,I²=29.0%),未发现主要INSTI相关突变。
要点
- 东非新启动ART成人合并PDR总患病率为10.0%(95%CI:7.9%-12.0%)。
- NNRTI类PDR患病率9.4%,高于NRTI类的2.6%和PI类的0.7%。
- 未发现主要INSTI相关突变,支持WHO以INSTI替代NNRTI的推荐。
核心结论
- 东非新启动ART者中观察到中等程度的总体PDR患病率,NNRTI类PDR更常见,凸显了当前WHO关于以INSTI替代NNRTI推荐的重要性。
- NRTI类PDR虽低但值得注意,需要对东非与多替拉韦联用的NRTI的既存耐药进行持续监测。
研究设计与样本
- 系统综述与Meta分析,系统检索2017年1月1日至2022年4月30日发表的文献,检索MEDLINE Complete、CINAHL Complete(经EBSCOhost同时检索)与Web of Science。
- 共纳入22项符合条件的观察性研究,合计5852例未接受抗逆转录病毒治疗的HIV感染者,使用Stata 14.2分析患病率。
主要发现
- 合并PDR总患病率为10.0%(95%CI:7.9%-12.0%,I²=88.9%)。
- NNRTI类PDR患病率为9.4%(95%CI:7.0%-11.9%,I²=90.4%)。
- NRTI类PDR患病率为2.6%(95%CI:1.8%-3.4%,I²=69.2%)。
- PI类PDR患病率为0.7%(95%CI:0.3%-1.2%,I²=29.0%)。
- 未发现主要整合酶链转移抑制剂(INSTI)相关突变。
临床怎么用
- 作者指出,当前WHO推荐以INSTI替代NNRTI;作者认为需要对东非与多替拉韦联用的NRTI的既存耐药进行持续监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-treatment HIV drug resistance (PDR) may result in increased risk of virological failure and acquisition of new resistance mutations. With recently increasing ART coverage and periodic modifications of the guidelines for HIV treatment, there is a need for an updated systematic review to assess the levels of the PDR among adults newly initiating ART in Eastern Africa. METHODS: We conducted a systematic search for studies published between 1 January 2017 and 30 April 2022 in the MEDLINE Complete and CINAHL Complete, searched simultaneously using EBSCOhost, and Web of Science. To determine the overall PDR prevalence estimates, we extracted data from eligible articles and analysed prevalence estimates using Stata 14.2. RESULTS: A total of 22 eligible observation studies were selected. The studies included a total of 5852 ART-naive people living with HIV. The overall pooled prevalence of PDR was 10.0% (95% CI: 7.9%-12.0%, I2 = 88.9%) and 9.4% (95% CI: 7.0%-11.9%, I2 = 90.4%) for NNRTIs, 2.6% (95% CI: 1.8%-3.4%, I2 = 69.2%) for NRTIs and 0.7% (95% CI: 0.3%-1.2%, I2 = 29.0%) for PIs. No major integrase strand transfer inhibitors (INSTI)-related mutations were identified. CONCLUSIONS: We observed a moderate overall PDR prevalence among new ART initiators in this study. PDR to NNRTIs is more prevalent, underscoring the importance of the current WHO recommendation for replacement of NNRTIs by INSTIs. PDR to NRTIs was low but notable, which warrants continuous surveillance of pre-existing resistance to the dolutegravir co-administered NRTI in Eastern Africa.
引用
- Ntamatungiro AJ, Kagura J, Weisser M, et al. Pre-treatment HIV-1 drug resistance in antiretroviral therapy-naive adults in Eastern Africa: a systematic review and meta-analysis. J Antimicrob Chemother. 2022. PMID: 36225089. doi:10.1093/jac/dkac338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。